Newly detected atrial fibrillation in patients with an implantable cardioverter-defibrillator is a strong risk marker of increased mortality

Heart Rhythm

Volumn 6, Issue 1, 2009, Pages 2-8

  Bunch, T Jared ^a   Day, John D ^b   Olshansky, Brian ^c   Stolen, Kira Q ^d   Mullin, Christopher M ^e  

^a MAYO CLINIC   (United States)

^b INTERMOUNTAIN MEDICAL CENTER   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d Boston Scientific CRM   (United States)

^e Integra Group   (United States)

Author keywords

Arrhythmia; Atrium; Fibrillation; Heart failure; Mortality

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANAMNESIS; ARTICLE; CONTROLLED STUDY; DEFIBRILLATOR; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; IMPLANTATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; CAUSE OF DEATH; DEFIBRILLATORS, IMPLANTABLE; DISEASE PROGRESSION; ELECTRIC COUNTERSHOCK; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 58049135200     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2008.09.025     Document Type: Article

References (25)

1. Krahn A.D., Manfreda J., Tate R.B., et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 98 (1995) 476-484
2. Kannel W.B., Abbott R.D., Savage D.D., et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 306 (1982) 1018-1022
3. Carson P.E., Johnson G.R., Dunkman W.B., et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 87 6 Suppl (1993) VI102-VI110
4. Dries D.L., Exner D.V., Gersh B.J., et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 32 (1998) 695-703
5. Chugh S.S., Blackshear J.L., Shen W.K., et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 37 (2001) 371-378
6. Benjamin E.J., Wolf P.A., D'Agostino R.B., et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98 (1998) 946-952
7. Wyse D.G., Love J.C., Yao Q., et al. Atrial fibrillation: a risk factor for increased mortality-an AVID registry analysis. J Interv Card Electrophysiol 5 (2001) 267-273
8. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 327 (1992) 685-691
9. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 (1991) 303-310
10. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316 (1987) 1429-1435
11. Brophy J.M., Joseph L., and Rouleau J.L. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 134 (2001) 550-560
12. Crijns H.J., Tjeerdsma G., de Kam P.J., et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 21 (2000) 1238-1245
13. Stevenson W.G., Stevenson L.W., Middlekauff H.R., et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 28 (1996) 1458-1463
14. Wang T.J., Larson M.G., Levy D., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107 (2003) 2920-2925
15. Corell P., Gustafsson F., Schou M., et al. Prevalence and prognostic significance of atrial fibrillation in outpatients with heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 9 (2007) 258-265
16. Rienstra M., Smit M.D., Nieuwland W., et al. Persistent atrial fibrillation is associated with appropriate shocks and heart failure in patients with left ventricular dysfunction treated with an implantable cardioverter defibrillator. Am Heart J 153 (2007) 120-126
17. Olshansky B., Day J., McGuire M., et al. Reduction of right ventricular pacing in patients with dual-chamber ICDs. Pacing Clin Electrophysiol 29 (2006) 237-243
18. Olshansky B., Day J.D., Moore S., et al. Is dual-chamber programming inferior to single-chamber programming in an implantable cardioverter-defibrillator?. Results of the INTRINSIC RV (Inhibition of Unnecessary RV Pacing with AVSH in ICDs) study. Circulation 115 (2007) 9-16
19. Morris M.M., KenKnight B.H., and Lang D.J. Detection of atrial arrhythmia for cardiac rhythm management by implantable devices. J Electrocardiol 33 Suppl (2000) 133-139
20. Daoud E.G., Nademanee K., Fuenzalida C., et al. Clinical experience with tiered atrial therapies and atrial arrhythmia prevention algorithms in a dual chamber cardioverter defibrillator. J Cardiovasc Electrophysiol 17 (2006) 852-856
21. Miyasaka Y., Barnes M.E., Bailey K.R., et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol 49 (2007) 986-992
22. Bunch T.J., Hohnloser S.H., and Gersh B.J. Mechanisms of sudden cardiac death in myocardial infarction survivors: insights from the randomized trials of implantable cardioverter-defibrillators. Circulation 115 (2007) 2451-2457
23. Dorian P., Connolly S., Hohnloser S.H., et al. Why don't ICDs decrease all-cause mortality after MI?. Insights from the DINAMIT Study. Circulation 502 Suppl (2004) 2356
24. Goldenberg I., Moss A.J., McNitt S., et al. Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 (2006) 1811-1817
25. Daubert J.P., Zareba W., Cannom D.S., et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 51 (2008) 1357-1365